Q-omics provides the consensus-scored KRT27 profile across patient tissues and cancer cell-line models. KRT27 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT27 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, KRT27 RNA expression shows 8,399 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where KRT27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT27 survival associations across molecular data types. KRT27 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT27 RNA expression–survival associations across cancer types. High KRT27 expression shows unfavorable associations in KIRC and BLCA, but favorable associations in LIHC, ESCA, THYM and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT27 RNA expression.
This table summarizes KRT27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for KRT27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT27 shows lower tumor expression in COAD, LUAD, KICH, LUSC and BLCA and higher tumor expression in THCA. The COAD box plot shows higher KRT27 RNA expression in normal versus tumor tissue (log2 FC = −0.198, t-test p < 0.001).
This table shows molecular features associated with KRT27 in patient tissues and cancer cell lines. In patient samples, KRT27 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
